SCHEMBL3058848

SCHEMBL3058848

O=C(Cc1cc(C(=O)c2ccc3cc(-c4ccccc4)[nH]c3c2)sc1-c1ccccc1)NO

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
KMT2A Q03164 2/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
PPARG P37231 1/20 0.38
ITK Q08881 11/20 0.38
CHEK2 O96017 1/20 0.37
INSR P06213 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
GSK3B P49841 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3056696 0.90 CASP3 (0.55) CASP3SENP8SENP7SENP6KMT2A
SCHEMBL2682508 0.81 CASP3 (0.54) CASP3SENP8SENP7SENP6KMT2A
SCHEMBL3057661 0.80 KMT2A (0.58) KMT2ATP53ALOX15MAPK1MEN1
SCHEMBL3060581 0.79 KMT2A (0.49) KMT2ATP53ALOX15MAPK1MEN1
SCHEMBL14817330 0.77 CASP3 (0.37) CASP3SENP8SENP7SENP6KMT2A
SCHEMBL3042819 0.76 KMT2A (0.44) KMT2ATP53ALOX15MAPK1MEN1
SCHEMBL14817328 0.76 KMT2A (0.38) KMT2ATP53ALOX15MAPK1MEN1
SCHEMBL2683121 0.75 CASP3 (0.47) CASP3SENP8SENP7SENP6TP53
SCHEMBL3053709 0.73 KMT2A (0.41) KMT2ATP53ALOX15MAPK1MEN1
SCHEMBL14817329 0.73 KMT2A (0.36) KMT2ATP53ALOX15MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492428-B2 Small-molecule botulinum toxin inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2013-07-23 US disclosed
US-20100260778-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100260778-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS BTD, RAC2, BTN3A1 CASP3 2737/4885SENP8 2848/4885SENP7 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.